Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...